Objectives The early identification of factors contributing to the successful treatment of hepatitis C infection is important for researchers and clinicians. Studies carried out on the role of an ultrarapid viral response (URVR) for the prediction of a sustained viral response (SVR) have shown its high positive predictive value (PPV). However, data on the combined effect of URVR with IL28B genotypes for the prediction of SVR are lacking. Our aim was to study the role of URVR and IL28B genotypes in the prediction of SVR among patients in Georgia infected with genotype 1.
Introduction
Current estimates suggest that B180 million people are infected with the hepatitis C virus (HCV) worldwide, with the highest prevalence rates reported in Africa and Asia [1] . According to the WHO, as many as four million new infections occur annually and more than 350 000 individuals die from HCV-related liver diseases each year [1] . In Western countries, HCV is the leading cause of end-stage liver disease and hepatocellular carcinoma, as well as the main indication for liver transplantation [2] . HCV infection is currently curable using increasingly effective antivirals. Pegylated interferon a (pegIFN-a) and ribavirin combination therapy has been proven to be an effective treatment for individuals with chronic HCV infection [3] [4] [5] [6] .
Racial disparities have been reported for this recommended combination therapy with respect to the sustained viral response (SVR) rate, defined as the absence of HCV RNA in serum 6 months after the completion of treatment. An SVR of 20-28% has been reported among black patients compared with 40-52% among white patients with genotype 1 infection and 57 versus 82% for genotype 2 or 3 infection, respectively [7] [8] [9] [10] .
Sustained response rates of 61-79% were found among Asian patients infected with the HCV genotype 1 and 80-95% for Asian patients infected with genotype 2 or 3 [11] [12] [13] [14] [15] . These racial differences in the responses to treatment suggested a possible genetic influence on HCV treatment outcome.
Various other host characteristics have been identified to be associated with a favorable treatment outcome including female sex, younger age, absence of liver steatosis, and insulin resistance [3, 5, 6] . Being infected with HCV genotype 2 or 3 and having a low viral load are the key viral determinants associated with a successful treatment outcome. In addition, a rapid viral response (RVR) to treatment, that is, undetectable HCV RNA in serum, at week 4 and an early viral response (EVR) at week 12 are important therapeutic milestones that predict an SVR [16, 17] .
Studies of HCV viral kinetics during treatment have shown that IFN a-2b causes a rapid dose-dependent reduction in the HCV RNA levels in the serum within 24 -48 h. Mathematical calculations have shown that HCV has a serum half-life of 3 h and a viral production rate of 1.0 Â 10 12 virions/day [4, 18] . Therefore, a rapid viral decline after the initiation of treatment is a strong predictor of an SVR response to treatment [19, 20] .
The rapid initial decline is followed by a slower phase that varies widely among patients and is attributed to the death rate of infected hepatocytes. The second phase of viral decline, mediated by the immune clearance of infected and dead hepatocytes, is also related to viral clearance and SVR [21] .
The recent discovery of host genetic factors that influenced treatment outcome has altered the approach to HCV treatment. Three independent genome-wide association studies have identified single nucleotide polymorphisms (SNPs) near the gene coding for IFN l-3 (or IL28B) that are associated with a favorable response to antiviral treatment and spontaneous resolution of infection in patients infected with HCV genotype 1 [22] [23] [24] .
The identification of genetic variation in the IL28B gene region raised the possibility that the determination of the IL28B allele might have the potential to predict the response to therapy to alter the duration of treatment. Among the SNPs studied, rs12979860 located near the IL28B gene was reported to have the highest SVR predictive potential [25] . The rates of SVR among patients infected with genotype 1 and harboring an IL28B C/C genotype reached 80%. A high SVR rate was observed among genotype 2 and 3 patients harboring the IL28B genotype C/C who did not achieve an RVR during the treatment course [26] .
The ability to predict either a positive or a negative therapeutic response is of obvious benefit to clinicians and patients. The ability to predict the likelihood of a favorable treatment response as early as possible in the course of antiviral treatment could be beneficial to the treating physician and the patient. The reported studies of an ultrarapid viral response (URVR), a viral load reduction by more than 2 log at week 1 or 2, to therapy have found it to be predictive of an SVR. However, to our knowledge, data on the combined effect of URVR and IL28B genotypes for the prediction of SVR have not been reported widely.
The prevalence of HCV infection in Georgia, in the general population as well as in high-risk groups, is among the highest in Eastern European countries. The most comprehensive surveys of hepatitis in Georgia indicate that hepatitis C is widespread in the country [27] . Screening of 2000 randomly selected adults in Tbilisi, Georgia, in 2008 found an HCV seroprevalence of 6.7% [27] . These data indicate that the prevalence of HCV in Georgia is more than twice the global HCV prevalence estimate of 3% and is higher than other countries in the region [28] .
We have carried out a prospective cohort study to examine the role of viral and host characteristics in predicting SVR during interferon treatment among hepatitis C-infected individuals from Georgia. We have studied the utility of URVR and IL28B genotypes for the prediction of SVR among patients on antiviral treatment with interferon and ribavirin. This study is the first prospective cohort study to examine the HCV viral kinetics and host genetic markers in patients undergoing antiviral treatment in Georgia.
Materials and methods

Study population
Of 179 patients with chronic HCV infection seeking care at the Infectious Diseases, AIDS and Clinical Immunology Research Center (IDACIRC) in 2009-2010, 156 adult patients were eligible for the study on the basis of the following inclusion criteria: (a) detectable HCV viral load and HCV genotype 1; (b) no history of previous interferon treatment; and (c) liver fibrosis METAVIR scores of F2/F3. Patients who were coinfected with hepatitis B virus or HIV or diagnosed with autoimmune or alcoholic liver diseases were excluded. The study was approved by the IDACIRC's Institutional Review Board and all patients provided written consent to participate. Antiviral treatment included pegIFN-a-2a or pegIFN-a-2b at standard doses (180 or 1.5 mg/kg/week, respectively) and weight-adjusted ribavirin (1000 mg/day for genotype 1 patients weighing <75 kg and 1200 mg/day for patients weighing >75 kg, and 800 mg/day for genotypes 2 and 3, respectively) following current HCV treatment guidelines [29] . Patients infected with the HCV genotype 1 were treated for 48 weeks, whereas genotype 2 and 3 patients received 24 weeks of combination therapy according to the current treatment recommendations for HCV-monoinfected adults [29] . Treatment stopping rules were applied for patients with a suboptimal virologic response (< 2 log reduction of HCV RNA) at week 12 or a detectable virus at week 24 after achieving an EVR [29] .
Hepatitis C virus RNA viral load and genotyping
Plasma HCV RNA was determined using the COBAS TaqMan HCV Test, version 2 (Roche, Basel, Switzerland) with a detection limit of 25 IU/ml. Plasma samples for HCV viral load testing were collected at baseline, 3, 24, 48, and 72 h after the initial interferon injection and at 1, 2, 4, 12, 24, and 48 weeks. SVR was measured by HCV viral load testing at 24 weeks after the completion of treatment.
HCV genotyping was carried out by amplifying the 5 0 untranslated region of HCV (COBAS AMPLICOR HCV Test, version 2.0; Roche) and analyzing the amplification products using the Versant HCV Genotype version 2.0
LiPA strips (Innogenetics, Ghent, Belgium). The results were interpreted using the manufacturer's protocol.
IL28B genotyping
Human genomic DNA extracted from a blood specimen was used for the determination of the IL28B genotype. SNP rs12979860 was genotyped by allele-specific Taq-Man minor groove binding probes and the TaqMan Genotyping kit (Applied Biosystems, Foster City, California, USA) on an ABI 7500 Real-Time PCR System as described previously [30] . Allele-specific genotyping calls were automatically applied on the allelic discrimination plot upon the completion of real-time PCR amplification and detection. Three possible allelic calls were presented, distinguishing C/C, C/T, and T/T genotypes.
Liver fibrosis staging
Liver fibrosis was measured using transient elastography by FibroScan (Echosens, Paris, France). The median value per patient was expressed in kilopascal units. Moderate or significant liver fibrosis and its corresponding METAVIR scores F2 and F3 was defined for liver stiffness values of 6-9.5 kPa, on the basis of the results from studies carried out in both HCV-monoinfected and HIV/HCV-coinfected patients [31, 32] .
Statistical analyses
Univariate analysis was used to evaluate the distributions of variables. Comparisons were tested using Pearson's w 2 or Fisher's exact test as appropriate. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) with the respective 95% confidence intervals were calculated by IL28B genotype status to assess the predictive value of early viral decline for achieving an SVR. All statistical analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, North Carolina, USA). P values less than 0.05 were considered statistically significant.
Results
Of the total of 156 patients enrolled in the study, 13 (8.3%) discontinued treatment because of the sideeffects of interferon/ribavirin or other reasons and were not included in the final analyses. Of the remaining 143 patients, 103 (72.0%) completed the course of treatment; 40 patients (28.0%) terminated the treatment because of a suboptimal virologic response at week 12.
The majority of the patients were men (82.5%) and older than 23 years of age (mean age 38 years) ( Table 1 ). All were of white race and European ancestry. Of the 143 patients, 83 (58%) reported previous exposure to intravenous drugs, which was the likely source for their HCV acquisition. Eighty-four patients (58.7%) of 143 had a high viral load (> 600 000 IU/ml) at baseline and all were diagnosed with either moderate or significant liver fibrosis by the METAVIR score (6-9.5 kPa) on the basis of the criteria for study enrollment.
IL28B genotype analysis indicated that 76 patients (53.1%) were harboring C/T and T/T variants of SNP rs12979860, whereas the C/C genotype was found among 67 individuals (46.8%). A significantly greater proportion of patients with the C/C genotype had a high viral load (> 600 000 IU/ml) than those with the non-C/C group. As the predictive values for SVR among patients with unfavorable genotypes of C/T and T/T as well as among those with favorable HCV genotypes 2 and 3 were found to be similar, we have grouped them together in the final analyses.
The HCV genotype distribution among the cohort was as follows: 50 patients (34.9%) were infected with the HCV genotype 1 and 93 patients (65.1%) with HCV genotypes 2 and 3. An SVR was achieved in 23 (46%) patients infected with the HCV genotype 1 and among 67 (72%) patients infected with HCV genotypes 2 and 3.
Hepatitis C virus viral load decline; hepatitis C virus and IL28B genotypes
The rate of decline in the HCV viral load at each time point was calculated and compared between C/C and non-C/C groups. A decline in the HCV viral load of more than 2 log 10 at each time point compared with the baseline was considered to be a favorable virological response. The firstphase viral decline was defined as the decline in HCV RNA between baseline and day 3. No significant associations were found between the first-phase decline (at 3, 24, 48, and 72 h) and an SVR (data not shown). Data on the second-phase decline rate, namely, URVR at weeks 1 and 2, RVR, EVR, ETR, and IL28B and HCV genotypes are summarized in Table 2 .
When the on-treatment response rates among HCV genotype 1 patients were stratified according to the IL28B genotypes, the group harboring the C/C genotype showed a higher rate of viral decline at all second-phase time points, compared with the group harboring the C/T and T/T genotypes [P values at all time points were <0.05 ( Table 2) ]. Therefore, the T allele had a negative impact on the second-phase viral decline and was associated with lower rates of URVR at weeks 1 and 2, RVR and SVR ( Table 2 ).
Of 17 genotype 1 patients from the C/C group who achieved an SVR, eight patients attained URVR at weeks 1 and 2 with further RVR, EVR, and ETR. None of these eight patients had a breakthrough or relapsed after treatment completion. Conversely, URVR was not predictive of SVR in the non-C/C genotype 1 group ( Table 2) .
All second-phase viral load decline rates of genotype 2 and 3 patients harboring the C/C genotype were somewhat higher than those of the non-C/C group ( Table 2 ). The effect of IL28B C/C genotypes was only marginally significant on an URVR at weeks 1 and 2 and did not contribute to the later viral load decline rates ( Table 2) . When the HCV genotypes 2 and 3 group was stratified by HCV genotype, the C/C genotype was a slightly better predictor for URVR at weeks 1 and 2 and SVR among genotype 3 patients than it was for those infected with genotype 2 (data not shown).
Association of the hepatitis C virus baseline viral load, the IL28B genotype, and the prediction of a sustained viral response
The mean HCV viral load decline between baseline and URVR weeks 1 and 2 was calculated for all IL28B and HCV genotype groups. A greater HCV viral load decline was observed among the HCV genotype 1 C/C group, which was not associated with the baseline viral load. However, the decline in the non-C/C group was significantly associated with a low baseline viral load (P < 0.04). No differences were found among the genotypes 2 and 3 group in this respect (P > 0.05).
Predictive values of IL28B genotypes for a sustained viral response
An SVR was achieved by 77.2% of patients with HCV genotype 1 C/C versus 22.4% of patients with non-C/C. However, an SVR was achieved by 80% and 64.5% of patients whose genotypes were C/C and non-C/C among those infected with HCV genotypes 2 and 3, respectively ( Table 2 ). The rate of SVR among genotype 1 C/C patients not achieving URVR and RVR was greater compared with the non-C/C group (P < 0.05). However, the C/C genotype was not predictive of an SVR among genotype 2 and 3 patients without an URVR and an RVR (P > 0.05).
The PPV and NPV for an SVR at each second-phase time point are summarized in Table 3 . Combining the IL28B C/C genotype with either URVR at week 2 or RVR responses yielded a PPV of 100% and an NPV of 43-45%, whereas among the patients with the non-C/C genotype, the PPV was only 50% for URVR at week 2 and 75% for RVR and the NPV was 81% for URVR and 87% for RVR. The PPV and NPV values for each time point in the genotypes 2 and 3 group were similar between the two IL28B groups (data not shown).
Discussion
In addition to the HCV genotype, viral load, and liver fibrosis stage, recent studies have shown an association between certain host genetic factors and successful treatment outcome [23, 24] . Among the on-treatment predictors, a viral load decline of more than 2 log 10 at weeks 4 and 12 has been shown to have a high predictive value for achieving an SVR [17, 18] .
Because of the high cost of treatment and the relatively low effectiveness of the current treatment regimens among genotype 1 patients, it is important to identify markers that can reliably predict the likelihood of treatment success. Early prediction of treatment outcome is essential to ensure the continuation of and compliance with therapy among patients with a high likelihood of cure and deferring treatment when the chances of achieving an SVR are minimal.
Because of the high cost of antiviral treatment, neither the health system nor the insurance schemes in Georgia will cover the costs of hepatitis C treatment services. Therefore, less than 10% of the patients diagnosed with HCV infection who are in urgent need of antiviral treatment undergo antiviral therapy. Moreover, almost all of those patients have to pay for their treatment out of pocket, an option that is not feasible for most patients. Thus, the early identification of reliable markers of treatment success is of critical importance.
We have carried out a detailed evaluation of the first-phase and second-phase viral declines in conjunction with the identification of IL28B genotypes among patients with chronic HCV infections in Georgia who were receiving treatment with pegIFN and ribavirin. The main findings of our study were that among patients infected with HCV genotype 1 with homozygous C/C alleles, the viral load decline (> 2 log 10 ) at weeks 1 and 2 was highly predictive of an SVR (PPV-100%) and was as useful as an RVR in predicting a successful outcome of therapy. Therefore, the probability of achieving an SVR can be assessed as accurately at weeks 1 and 2 as at week 4 or 12. In addition, the chance of achieving an SVR among genotype 1 C/C patients without a URVR at weeks 1 and 2 or an RVR is greater than that in the non-C/C group. Therefore, according to our data, it is useful both to measure the presence of virological response to therapy at weeks 1 and 2 and to determine the IL28B genotype of HCV genotype 1 patients to predict the eventual probability of an SVR.
Our findings were consistent with those of Thompson et al. [33] , who reported that patients with the C/C genotype had the strongest viral reduction levels at week 2 compared with other IL28B genotypes and therefore were associated with an SVR. In addition, our study showed the effect of URVR at week 1 to be the earliest effective prediction time point for an SVR. This observation differed from the findings of Bochud et al. [34] and Arends et al. [35] . They reported the effect of viral load decline at 24 and 48 h as the earliest markers for the prediction of an SVR among C/C carriers. As the first-phase viral load decline is largely dependent on the fibrosis stage, as well as insulinemia and g-glutamyl transpeptidase levels, the differences observed in our cohort may be because of the demographic differences between the study populations. Despite the effect of C/C genotype in achieving higher URVR and SVR rates among genotype 2 and 3 patients, there was no significant association between C/C genotypes and viral reduction rates at week 4, although the RVR was higher among C/C carriers than those with C/T and T/T genotypes.
Our results were slightly different from those of Mangia et al. [26] and Rallon et al. [36] . Similar to Mangia's results, the rate of an SVR was high among patients who attained a URVR and an RVR irrespective of the IL28B genotype. However, unlike their reports, the C/C genotype was not predictive of an SVR among patients not achieving a URVR and an RVR. An unexplained observation was made in this group as the C/C genotype was a predictor for achieving a URVR and an SVR, but not attaining an RVR, EVR, and ETR. The numbers in IL28B genotype groups not achieving a URVR and an RVR were small; therefore, we cannot draw firm conclusions. However, we can speculate that a favorable IL28B genotype influences early viral kinetics and does not have a substantial effect in the later treatment course among genotype 2 and 3 patients. Thus, an RVR and not the IL28B genotype can be regarded as the better predictor for an SVR among genotype 2 and 3 patients unlike genotype 1 patients. Altogether, these observations suggest that different mechanisms of viral eradication may be operative during the early and late treatment course among patients infected with different HCV genotypes.
Our study has several important implications. First, it is the first study of HCV viral kinetics and IL28B genotypes among the Georgian population, who represent a highly homogeneous ethnic group. Second, we have identified a URVR at weeks 1 and 2 to be the earliest effective treatment predictor for SVR among C/C genotype carriers. Third, we found the influence of the C/C genotype for an SVR among patients in Georgia who were infected with different HCV genotypes. The effect of the C/C genotype among HCV genotype 1 patients is not only mediated by its effect on URVR and RVR but is still predictive of a favorable outcome of therapy among patients who do not achieve a URVR or an RVR. Finally, our data suggest that a favorable IL28B genotype might only influence the viral eradication early in the treatment course among genotype 2 and 3 patients and does not have a beneficial effect later during therapy among patients without a URVR and an RVR.
There were several important limitations to our study that should be considered. First, we did not have a large number of female participants in the study, which might have allowed us to evaluate the sex-related responses to interferon therapy among women with different IL28B genotypes. Second, because of the limited number of patients, we did not evaluate HCV treatment responses IL28B, viral decline in an HCV-infected cohort Karchava et al. 821 among genotype 1 patients with different subtypes. Third, the liver fibroses scores were evaluated by transient elastography and not liver biopsy, which some consider to be the gold standard for liver fibrosis evaluation. Nevertheless, transient elastography has been shown to accurately diagnose patients with advanced fibrosis and, that is, METAVIR scores of F2 or F3. Fourth, we do not have information on the liver enzymes or hepatic steatosis and insulinemia levels; these factors have been reported to be related to SVR responses to interferon treatment. Finally, we did not study the effect of other SNPs on interferon responses.
Our study demonstrates the importance of defining IL28B genotypes and URVR as the earliest prediction marker for SVR among HCV genotype 1-monoinfected Georgian patients undergoing antiviral therapy. In addition, genotype 1 patients who had an unfavorable IL28B genotype and did not achieve a URVR or an RVR had a minimal chance of eventually achieving an SVR; however, treatment discontinuation cannot be considered at this point. The predictive power of the IL28B genotype for an SVR continues to be significant beyond the early therapeutic course; however, an RVR is the most important predictor of an SVR among genotype 2 and 3 patients irrespective of the IL28B genotype. More research is needed to fully understand the predictive role of URVR and IL28B genotypes among larger patient groups including women and patients who are coinfected with the HIV or the hepatitis B virus.
